Seeking Alpha
Deep value, event-driven, dividend investing, REITs
Profile| Send Message|
( followers)  

For this particular screen, I wanted to focus on the second quarter and highlight the fact that each of the companies below has a minimum growth estimation of 50%, which is 4.85 times the projected growth of the S&P 500. Each of these three pharmaceutical companies is expected to demonstrate significant growth during the second quarter.

Vivus, Inc. (NASDAQ:VVUS): The company trades in a 52-week range of $6.13 (52-week low) to $29.99 (52-week high). It has traded up roughly 2% over the last few trading sessions and could continue to demonstrate similar behavior throughout the second half of the year. One the key catalysts for potential investors would be projected quarterly growth when compared to that of the S&P 500. Currently, VVUS is expected to grow at a rate of 65% for the quarter, which is 6.31 times that of the S&P 500, which is expected to only grow 10.3% for the quarter.

For potential investors looking to establish a position in VVUS, the company is expected to post a loss of $0.17/share on revenue of $17.05 million for the second quarter. Given the fact that the company has missed analysts' estimates three out of the last four quarters, an earnings estimate beat of at least 10% would positively contribute to the company's growth. In terms of establishing a position at these levels, a small- to medium-sized position would be acceptable at current levels. Investors should keep in mind that the company is awaiting an FDA ruling with regard to its weight-loss drug Qnexa.

SciClone Pharmaceuticals (NASDAQ:SCLN): The company, which trades in a 52-week range of $3.41 (52-week low) to $7.45 (52-week high), has traded up roughly 4.8% over the last few trading sessions and could continue to demonstrate similar behavior throughout the second half of the year. One the key catalysts for potential investors would be projected quarterly growth when compared to the S&P 500. Currently, SCLN is expected to grow at rate of 200% for the quarter, which is 19.41 times that of the S&P 500, which is expected to only grow 10.3% for the quarter.

For potential investors looking to establish a position in SCLN, the company is expected to post a profit of $0.18/share on revenue of $41.98 million for the second quarter. Given the fact that the company has surpassed analysts' estimates in the last four quarters, another earnings estimate beat of at least 15% would positively contribute to the company's growth. In terms of establishing a position at these levels, a small- to medium-sized position would be acceptable at current levels, and more shares should be added as earnings announcements approach.

Celsion Corp. (NASDAQ:CLSN): The company trades in a 52-week range of $1.63 (52-week low) to $4.37 (52-week high) and has traded up roughly 26% over the last few trading sessions. It could continue to demonstrate similar behavior throughout the second half of the year. One of the key catalysts for potential investors would be projected quarterly growth when compared to that of the S&P 500. Currently, SCLN is expected to grow at rate of 50% for the quarter, which is 4.85 times that of the S&P 500, which is expected to only grow 10.3% for the quarter.

For potential investors looking to establish a position in SCLN, the company is expected to post a loss of $0.19/share for the second quarter. Given the fact that the company has surpassed analysts' estimates three of the last four quarters, an earnings estimate beat of at least 15% would positively contribute to the company's growth. In terms of establishing a position at these levels, a small- to medium-sized position would be acceptable at current levels, and more shares should be added as earnings and positive drug development announcements approach.

Source: 3 Promising Pharma Companies Projected To Grow 5 Times Faster Than The S&P 500